Projects

PharmDr. Tereza Goliaš, PhD.

National

Current
  • Study of inverse relationship between carbonic anhydrases CA IX and CA IV and its significance for tumor phenotype
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Carbon dioxide in cancer glucose metabolism: an overlooked Achilles’ heel of cancer
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Metabolic profiling of testicular cancer cells to increase the sensitivity of resistant cells to cisplatin
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
Finished
  • Infrastructure for the study of carbon dioxide in tumor glucose metabolism
    Program:
    Duration: 1. 7. 2024 – 30. 6. 2025
  • Unraveling the mechanisms linking obesity and cancer progression: the interplay between adipocytes and cancer cells
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Regulation of pyruvate dehydrogenase kinase 1 activity in the control of glycolytic metabolism in hypoxic tumors
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Interaction of hypoxia with the signaling pathways implicated in differentiation, tumor progression and metastasis.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Targeting carbonic anhydrase IX and pyruvate dehydrogenase kinase 1 in hypoxic colorectal tumors
    Program: SASPRO
    Duration: 1. 6. 2015 – 31. 12. 2018
  • The role of carbonic anhydrase IX in tumor metabolism: regulation, function and clinical significance
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2011 – 31. 10. 2015
  • Significance of the carbonic anhydrase IX as a non-invasive prognostic indicator and a molecular target in renal cell carcinoma
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Extracelular form of hypoxia - induced tumor - associated carbonic adhydrase IX /CA IX/: molecular mechanisms of shedding and biological significance in oncogenesis
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
  • Regulation of expression and role of TEM1/endosialin/CD248, a potential marker of tumor angiogenesis
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
  • -
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees